Bristol Myers Squibb announced FDA approval of Cobenfy (KarXT or Xanomeline and Trospium), and the exciting results published recently in The American Journal of Psychiatry showcasing the use of Cambridge Cognition's CANTAB product in two Phase 3 clinical trials in patients with schizophrenia. Marking a significant advancement in schizophrenia treatment, Cobenfy is the first new drug in decades and targets the M1 and M4 muscarinic receptors, compared to antipsychotics which block dopamine receptors. This approach reduces both the positive and negative symptoms of schizophrenia more effectively.